Hyperkalemia as a manifestation of paraneoplastic syndrome in esophageal cancer: a case report
D. N. Kostromitskiy,
A. Yu. Dobrodeev,
D. P. Koval,
S. G. Afanasyev,
A. S. Tarasova,
S. V. Vtorushin https://doi.org/10.25789/YMJ.2026.93.29
Abstract
Paraneoplastic syndromes are clinical manifestations associated with malignant neoplasms that are not directly related to local tumor growth or metastatic spread. They may significantly complicate diagnosis and treatment planning in cancer patients. Paraneoplastic syndromes are most commonly described in lung, breast, and pancreatic cancers, whereas such manifestations are extremely rare in esophageal cancer. This article presents a clinical case of esophageal adenocarcinoma complicated by persistent hyperkalemia, regarded as a manifestation of a paraneoplastic syndrome. The electrolyte disturbance was resistant to medical correction, which made standard chemotherapy and surgical treatment impossible. External beam radiotherapy to the primary tumor and regional lymphatic pathways was used as the first stage of treatment, resulting in normalization of serum potassium levels. This allowed subsequent neoadjuvant chemotherapy followed by radical surgical intervention, achieving a complete pathological response. The presented case highlights the importance of recognizing paraneoplastic electrolyte disorders in esophageal cancer and demonstrates the significance of an individualized treatment approach in patients with atypical disease course.
About the Authors
D. N. Kostromitskiy
Научно-исследовательский институт онкологии, ФГБНУ «Томский национальный исследовательский медицинский центр Российской академии наук»
Russian Federation
Russian Federation
A. Yu. Dobrodeev
Научно-исследовательский институт онкологии, ФГБНУ «Томский национальный исследовательский медицинский центр Российской академии наук»
Russian Federation
Russian Federation
D. P. Koval
ФГБОУ ВО «Сибирский государственный медицинский университет» Минздрава России
Russian Federation
Russian Federation
S. G. Afanasyev
Научно-исследовательский институт онкологии, ФГБНУ «Томский национальный исследовательский медицинский центр Российской академии наук»
Russian Federation
Russian Federation
A. S. Tarasova
Научно-исследовательский институт онкологии, ФГБНУ «Томский национальный исследовательский медицинский центр Российской академии наук»
Russian Federation
Russian Federation
S. V. Vtorushin
Научно-исследовательский институт онкологии, ФГБНУ «Томский национальный исследовательский медицинский центр Российской академии наук»;
ФГБОУ ВО «Сибирский государственный медицинский университет» Минздрава России
Russian Federation
Russian Federation
References
1. Strauss A. Phlegmasia alba dolens in Clinique Medicale de l'Hotel-Dieu de Paris. Bailliere. 1865; 3: 654-712.
2. Oppenheim H. Über Hirnsymptome bei Carcinomatose ohne nachweisbare Veränderungen im Gehirn. Charité Annalen. 1888;13:335–344.
3. Guichard A., Vignon G. La polyradiculonévrite cancéreuse métastatique; paralysies multiples des nerfs craniens et rachidiens par généralisation microscopique d'un épithélioma du colutérin [Metastatic cancer polyradiculoneuritis; Multiple paralysis of the cranial and spinal nerves by microscopic generalization of an epithelioma of the colutein]. J Med Lyon. 1949 Mar 5;30(700):197-207. J.Med Lyon 1949:30: 197- 207.
4. Henry K. Paraneoplastic syndromes: Definitions, classification, pathophysiology and principles of treatment. Semin Diagn Pathol. 2019 Jul;36(4):204-210. https://doi.org/10.1053/j.semdp.2019.01.002.
5. Sardiña González C., Martínez Vivero C., López Castro J. Paraneoplastic syndromes review: The great forgotten ones. Crit Rev Oncol Hematol. 2022 Jun;174:103676. https://doi.org/10.1016/j.critrevonc.2022.103676.
6. Thapa B., Mahendraker N., Ramphul K. Paraneoplastic Syndromes. 2023 Mar 31. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan. PMID: 29939667.
7. Onyema M.C., Drakou E.E., Dimitriadis G.K.. Endocrine abnormality in paraneoplastic syndrome. Best Pract Res Clin Endocrinol Metab. 2022 May;36(3):101621. https://doi.org/10.1016/j.beem.2022.101621.
8. Reisch N., Reincke M. Endokrine paraneoplastische Syndrome [Endocrine paraneoplastic syndromes]. Internist (Berl). 2018 Feb;59(2):125- 133. German. https://doi.org/10.1007/s00108-017-0377-y.
9. Rashidi A., Youssef N., Workeneh B., et al. Electrolytes Abnormalities in Cancer Patients. Am J Nephrol. 2025 Feb 25:1-20. https://doi.org/10.1159/000544877.
10. Berardi R., Torniai M., Lenci E., et al. Electrolyte disorders in cancer patients: a systematic review. J Cancer Metastasis Treat. 2019;5:79. https://doi.org/10.20517/2394-4722.2019.008.
11. Ratanasrimetha P., Workeneh B.T., Seethapathy H. Sodium and Potassium Dysregulation in the Patient With Cancer. Adv Chronic Kidney Dis. 2022 Mar;29(2):171-179.e1. https://doi.org/10.1053/j.ackd.2022.01.003.
12. Tong X., Jin M., Wang L., et al. Prognostic biomarkers for immunotherapy in esophageal cancer. Front Immunol. 2024 Sep 30;15:1420399. https://doi.org/10.3389/fimmu.2024.1420399.
13. Mac Eochagain, C., Ronan, K., Flynn, C., et al. (2023). Paraneoplastic syndromes in esophageal cancer—a narrative review. Annals of Esophagus, 6.
14. Hoeppner J., Brunner T., Schmoor C., et al. Perioperative Chemotherapy or Preoperative Chemoradiotherapy in Esophageal Cancer. N Engl J Med. 2025 Jan 23;392(4):323-335. https://doi.org/10.1056/NEJMoa2409408.
15. Agoston A.T., Srivastava A., Zheng Y., et al. Paraneoplastic thrombocytosis is associated with increased mortality and increased rate of lymph node metastasis in oesophageal adenocarcinoma. Pathology. 2017 Aug;49(5):471-475. https://doi.org/10.1016/j.pathol.2017.04.001.
16. Chang K.W., Kwok L.L., Rana M.K., et al. Paraneoplastic Leukemoid Reaction in Gastroesophageal Junction Adenocarcinoma: A Case Report. Am J Case Rep. 2020 Jan 31;21:e919596. https://doi.org/10.12659/AJCR.919596.
17. Yu G., Ji H., Meng C.,et al. Esophageal adenocarcinoma with leukemoid reaction: a case report. J Cardiothorac Surg. 2019 Apr 8;14(1):66. doi: 10.1186/s13019-019-0893-z.
18. Almutlaq M., Alamro A.A., Alamri H.S., et al. The Effect of Local Renin Angiotensin System in the Common Types of Cancer. Front Endocrinol (Lausanne). 2021 Sep 3;12:736361. https://doi.org/10.3389/fendo.2021.736361.
19. Goodman K.A., Ou F.S., Hall N.C., et al. Randomized Phase II Study of PET Response-Adapted Combined Modality Therapy for Esophageal Cancer: Mature Results of the CALGB 80803 (Alliance) Trial. J Clin Oncol. 2021 Sep 1;39(25):2803-2815. https://doi.org/10.1200/JCO.20.03611.
20. Wainberg Z.A., Lin L.S., DiCarlo B., et al. Phase II trial of modified FOLFOX6 and erlotinib in patients with metastatic or advanced adenocarcinoma of the oesophagus and gastro-oesophageal junction. Br J Cancer. 2011 Sep 6;105(6):760-5. https://doi.org/10.1038/bjc.2011.280.
Review
For citations:
Kostromitskiy D.N., Dobrodeev A.Yu., Koval D.P., Afanasyev S.G., Tarasova A.S., Vtorushin S.V. Hyperkalemia as a manifestation of paraneoplastic syndrome in esophageal cancer: a case report. Yakut Medical Journal. 2026;(1):136-140. (In Russ.) https://doi.org/10.25789/YMJ.2026.93.29
Views:
46
JATS XML
Email this article 